Login to Your Account



Avastin Combo 'Azure' Thing?

After Phase IIb Fizzle, Cerulean Forges Ahead with Nano Work

By Randy Osborne
Staff Writer

Monday, March 25, 2013
Although Cerulean Pharma Inc.'s farthest-along trial with nanoparticle-based, camptothecin-loaded CRLX101 missed its endpoint in a Phase IIb trial against advanced non-small-cell lung cancer (NSCLC), a handful of other studies are ongoing and all have "a very strong biological rationale underpinning" them, said Oliver Fetzer, president and CEO of the Cambridge, Mass.-based firm.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription